Table 1.
Patient characteristics for n = 18 patients who completed the QLQ-C15-PAL and QLQ-BM22 questionnaires at baseline and at least two other follow-up time points
| Age (years) | |
| Mean ± standard deviation | 55 ± 11 |
| Median (range) | 57 (36–72) |
| Gender | |
| Male | 9 (50.0%) |
| Female | 9 (50.0%) |
| Country | |
| UK | 9 (50.0%) |
| South Korea | 5 (27.8%) |
| Netherlands | 4 (22.2%) |
| Primary tumour site | |
| Breast | 7 (38.9%) |
| Lung | 4 (22.2%) |
| Liver | 4 (22.2%) |
| Renal | 3 (16.7%) |
| Karnofsky performance status | |
| Mean ± standard deviation | 82 ± 8 |
| Median (range) | 80 (70–100) |
| MR-guided HIFU treatment site | |
| Pelvis | 14 (77.8%) |
| Arm | 2 (11.1%) |
| Leg | 1 (5.6%) |
| Rib | 1 (5.6%) |
| Prior radiotherapy to target lesion | |
| 8 Gy 1 fraction | 2 (11.1%) |
| 20 Gy 5 fractions | 3 (16.7%) |
| 30 Gy 10 fractions | 4 (22.2%) |
| High dose >30 Gy, or multiple treatments | 9 (50.0%) |
| Responder to prior radiotherapy? (complete or partial) | 7 (38.9%) |
| Number of months radiotherapy to HIFU screening: median (range) | 5 (1–57) |
| Number of painful sites (n = 16) | |
| Mean ± standard deviation | 2 ± 1 |
| Median (range) | 2 (1–6) |
| NRS worst pain score | |
| Mean ± standard deviation | 7 ± 1 |
| Median (range) | 7 (3–9) |
| MEDD∗ (mg) | |
| Median (range) | 10 (0–1000)† |
MR-guided HIFU, magnetic resonance-guided high intensity focused ultrasound; MEDD, morphine equivalent daily dose; NRS, numerical rating scale.
∗
The conversion ratios for calculating MEDD were as follows: 1 mg oral oxycodone = 2 mg oral morphine, 1 μg/h fentanyl patch = 3.3 mg oral morphine, 12 mg oral codeine = 1 mg oral morphine.
†
In one case, the calculated MEDD was >1000 mg, but conversion is inaccurate at these doses, and so the value was censored to 1000 mg.